Conexeu Sciences (CNXU) Director Purcell Buys $500K of Stock

By TradeTexts Research Desk Oct 19, 2026, 5:02 PM EDT

Key Points

Director Lynn Sebastian Purcell bought 166,666 shares of Conexeu Sciences Inc. at $3.00 per share on October 15, 2026.
The purchase lifted Purcell's total holding to 3,118,514 shares, representing a 5.65% increase in ownership.
Conexeu Sciences trades below its October 15 close of $3.95, recently hovering around $3.29 per share.

Since the trade, $CNXU is down 16.7% to date (from the $3.95 close on Oct 15, 2026).

Get Conexeu Sciences text alerts

We text you when insiders, Congress, analysts or big funds move on $CNXU.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Conexeu Sciences Inc. alert may contain errors. Disclosures

Conexeu Sciences Inc. (NasdaqCM: CNXU) director Lynn Sebastian Purcell bought 166,666 shares of the company stock on October 15, 2026. The transaction was revealed in a Form 4 filing with the Securities and Exchange Commission. The shares were acquired at a price of $3.00 each, totaling $499,998.

CNXU Conexeu Sciences Inc.

$3.29 -66.53% past 3 months

Daily close · Oct 19, 2026

Inside Lynn Sebastian Purcell's Trade

Following the October 15 transaction, Purcell held 3,118,514 shares of Conexeu Sciences. This purchase increased Purcell's stake by 5.65%. The trade was not made pursuant to a pre-arranged Rule 10b5-1 trading plan. Purcell serves as a director and holds more than 10% of a class of security for the biotech firm.

Other Institutional Activity in Conexeu Sciences

Citigroup Inc. grew its holdings by 2,610 shares in the period ended June 30, 2026, ending with 5,219 shares worth about $17,170. Hollencrest Capital Management grew its holdings by 500 shares, ending with 1,000 shares worth about $3,289. Royal Bank of Canada grew its holdings by 444 shares, ending with 887 shares worth about $2,918. Jones Financial Companies, L.L.L.P. grew its holdings by 50 shares, ending with 100 shares worth about $328. Osaic Holdings Inc. grew its holdings by 50 shares, ending with 100 shares worth about $328.

Conexeu Sciences Inc. Stock Down 33.7%

The stock closed at $3.95 on the transaction date of October 15, 2026. More recently, as of October 19, 2026, shares traded around $3.29, which is 16.7% below that event-day close.

Recent Earnings

Conexeu Sciences operates without positive trailing-twelve-month earnings, reporting an EPS of -0.5.

Insider Buying and Selling at Conexeu Sciences Inc.

This transaction follows earlier purchases by Purcell and other insiders earlier in the year. On May 12, 2026, Purcell bought 422,500 shares at $0.80 per share for a total of $338,000. Onepointtwo Capital Ventures LLC also bought 422,500 shares at $0.80 per share on May 12, 2026. Later, on June 18, 2026, Purcell bought 202,500 shares at $13.28 per share for $2,689,200.

Analysts Set New Price Targets

HC Wainwright & Co. initiated coverage on Conexeu Sciences with a buy rating and a $20.00 price target on June 22, 2026.

About Conexeu Sciences

Conexeu Sciences Inc. is a Reno, Nevada-based healthcare company focused on biotechnology. The firm develops collagen-based regenerative tissue scaffold products. These products serve applications in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring.

Bottom Line

Purcell's latest purchase adds to a series of insider trades recorded earlier this year. Investors will monitor upcoming filings and financial updates to track institutional and insider sentiment in the company.